BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 29705861)

  • 1. The prognostic role of E2A-PBX1 expression detected by real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) in B cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
    Hong Y; Zhao X; Qin Y; Zhou S; Chang Y; Wang Y; Zhang X; Xu L; Huang X
    Ann Hematol; 2018 Sep; 97(9):1547-1554. PubMed ID: 29705861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical significance of monitoring E2A- PBX1 fusion gene expression in patients with allogeneic hematopoietic stem cell transplantation].
    Zhao X; Qin Y; Zhang Y; Xu Y; Wang Y; Chen H; Wang F; Wang J; Huang X
    Zhonghua Xue Ye Xue Za Zhi; 2015 Dec; 36(12):989-93. PubMed ID: 26759098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Real-time quantitative detection of E2A-PBX1 fusion gene in children with acute lymphoblastic leukemia and its clinical application in minimal residual disease monitoring].
    Zhang R; Liao J; Li G; Sun HQ; Shi YJ; Yang JY
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Jun; 15(6):440-3. PubMed ID: 23791058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Correlation of E2a-pbx1 expression level with clinical characteristics and early response to treatment in children with acute lymphoblastic leukemia].
    Gao C; Li ZG; Zhao W; Wu MY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):569-73. PubMed ID: 18549631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical significance of monitoring the expression of the SIL-TAL1 fusion gene in T-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
    Zhao X; Hong Y; Qin Y; Xu Y; Chang Y; Wang Y; Zhang X; Xu L; Huang X
    Int J Lab Hematol; 2017 Dec; 39(6):613-619. PubMed ID: 28736882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical outcomes and genomic landscapes of acute lymphoblastic leukemia patients with E2A-PBX1: A 10-year retrospective study.
    Zhou B; Chu X; Tian H; Liu T; Liu H; Gao W; Chen S; Hu S; Wu D; Xu Y
    Am J Hematol; 2021 Nov; 96(11):1461-1471. PubMed ID: 34406703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.
    Zhang J; Yang F; Qiu HY; Wu Q; Kong DQ; Zhou J; Han Y; Wu DP
    Leuk Lymphoma; 2019 Jun; 60(6):1454-1461. PubMed ID: 30714847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical significance of monitoring ETV6-RUNX1 fusion gene expression in children with acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
    Hong Y; Qin YZ; Xu YY; Zhou SH; Wang Y; Xu LP; Zhang XH; Huang XJ; Zhao XS
    Zhonghua Xue Ye Xue Za Zhi; 2017 Aug; 38(8):680-684. PubMed ID: 28954346
    [No Abstract]   [Full Text] [Related]  

  • 9. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
    Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
    Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
    Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
    Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal residual disease after allogeneic stem cell transplant: a comparison among multiparametric flow cytometry, Wilms tumor 1 expression and chimerism status (Complete chimerism versus Low Level Mixed Chimerism) in acute leukemia.
    Rossi G; Carella AM; Minervini MM; Savino L; Fontana A; Pellegrini F; Greco MM; Merla E; Quarta G; Loseto G; Capalbo S; Palumbo G; Cascavilla N
    Leuk Lymphoma; 2013 Dec; 54(12):2660-6. PubMed ID: 23547840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation.
    Zhao XS; Liu YR; Zhu HH; Xu LP; Liu DH; Liu KY; Huang XJ
    Ann Hematol; 2012 Feb; 91(2):183-92. PubMed ID: 21710165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Evaluation of the efficacy of two successive protocols on pediatric acute lymphoblastic leukemia with E2A-PBX1 fusion gene].
    Mei YY; Gao C; Cui L; Zhao XX; Zhao W; Li WJ; Wang KL; Jiang J; Zhang RD; Xie J; Shi HW; Wang B; Zhang YH; Ma XL; Zhou X; Wu MY; Li ZG
    Zhonghua Er Ke Za Zhi; 2013 Jun; 51(6):467-71. PubMed ID: 24120066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence of E2A/PBX1 transcripts in t(1;19) childhood acute lymphoblastic leukemia: correlation with chemotherapy intensity and clinical outcome.
    Lanza C; Gottardi E; Gaidano G; Vivenza C; Parziale A; Perfetto F; Fornaci M; Barisone E; Madon E; Basso G; Saglio G
    Leuk Res; 1996 May; 20(5):441-3. PubMed ID: 8683984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concordance of two approaches in monitoring of minimal residual disease in B-precursor acute lymphoblastic leukemia: Fusion transcripts and leukemia-associated immunophenotypes.
    Huang YJ; Coustan-Smith E; Kao HW; Liu HC; Chen SH; Hsiao CC; Yang CP; Jaing TH; Yeh TC; Kuo MC; Lai CL; Chang CH; Campana D; Liang DC; Shih LY
    J Formos Med Assoc; 2017 Oct; 116(10):774-781. PubMed ID: 28063722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of SET-NUP214 fusion gene in acute leukemia after allogeneic hematopoietic stem cell transplantation.
    Gao MG; Hong Y; Qin YZ; Chang YJ; Wang Y; Zhang XH; Xu LP; Huang XJ; Zhao XS
    Medicine (Baltimore); 2020 Dec; 99(50):e23569. PubMed ID: 33327316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring of post-transplant MLL-PTD as minimal residual disease can predict relapse after allogeneic HSCT in patients with acute myeloid leukemia and myelodysplastic syndrome.
    Kong J; Gao MG; Qin YZ; Wang Y; Yan CH; Sun YQ; Chang YJ; Xu LP; Zhang XH; Liu KY; Huang XJ; Zhao XS
    BMC Cancer; 2022 Jan; 22(1):11. PubMed ID: 34979982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The applicability of multiparameter flow cytometry for the detection of minimal residual disease using different-from-normal panels to predict relapse in patients with acute myeloid leukemia after allogeneic transplantation.
    Wang Z; Guo M; Zhang Y; Xu S; Cheng H; Wu J; Zhang W; Hu X; Yang J; Wang J; Tang G
    Int J Lab Hematol; 2019 Oct; 41(5):607-614. PubMed ID: 31162830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Analysis of Flow Cytometry and RQ-PCR for the Detection of Minimal Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia after Hematopoietic Stem Cell Transplantation.
    Zhao X; Zhao X; Chen H; Qin Y; Xu L; Zhang X; Liu K; Huang X; Chang YJ
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1936-1943. PubMed ID: 29572111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Identification of proteins associated with transcription factors HOXA9 and E2A-PBX1 by tandem affinity purification].
    Shestakova EA; Boutin M; Bourassa S; Bonneil E; Bijl JJ
    Mol Biol (Mosk); 2017; 51(3):490-501. PubMed ID: 28707666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.